在比尔·盖茨建议牛津放弃开源COVID疫苗后,穷国却不为所动
西方跨国公司,包括牛津的私人合作伙伴阿斯利康(AstraZeneca),无法获得免疫穷国的利润,因此优先考虑那些支付最高费用的国家。
西方跨国公司,包括牛津的私人合作伙伴阿斯利康(AstraZeneca),无法获得免疫穷国的利润,因此优先考虑那些支付最高费用的国家。
“牛津疫苗令人震惊,因为要点是要向研究人员付款,而不是依靠专利垄断来产生丰厚的利润。” -经济学家Dean Baker
The world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success,
Alan MacLeod is Senior Staff Writer for MintPress News. After completing his PhD in 2017 he published two books: Bad News From Venezuela: Twenty Years of Fake News and Misreporting and Propaganda in the Information Age: Still Manufacturing Consent, as well as a number of academic articles. He has also contributed to FAIR.org, The Guardian, Salon, The Grayzone, Jacobin Magazine, and Common Dreams.